Prochlorperazine-Induced Hemidystonia as Stroke Mimic

Study Background and Research Question

Acute ischemic stroke requires rapid assessment because the benefit of intravenous fibrinolytic therapy is strongly time-dependent. However, speed must be balanced against diagnostic uncertainty, treatment contraindications, and the possibility that a nonvascular disorder is producing focal neurological findings. The reference article, Mimicking Acute Stroke, addresses this tension through a detailed emergency medicine case report of prochlorperazine-induced hemidystonia. The authors’ central question was whether an acute, unilateral stroke-like presentation could instead reflect an extrapyramidal adverse drug reaction.

Prochlorperazine is a phenothiazine and dopamine D2 receptor antagonist widely used in antiemetic therapy, including treatment of refractory nausea and migraine-related symptoms. Dopamine receptor blockade can also produce extrapyramidal symptoms such as akathisia, dystonia, and other abnormal involuntary movements. In the reported case, the neurological presentation was initially concerning enough to activate a formal stroke response. The article therefore examines not only an uncommon adverse effect, but also the diagnostic process required when medication toxicity and cerebrovascular disease overlap. The full case and authors’ interpretation are available in the reference study.

Key Innovation from the Reference Study

The main innovation is clinical rather than technological: the report identifies prochlorperazine-induced hemidystonia as a plausible and reversible stroke mimic. The authors describe the case as the first reported instance of this specific presentation in the literature, while appropriately presenting that conclusion as a case-report observation rather than an estimate of frequency.

The diagnostic value came from linking several observations that initially appeared discordant. The patient reported abrupt dysarthria, paresthesias, and severe left-sided weakness, yet her face remained symmetric, she could follow commands, and routine laboratory testing did not reveal a metabolic or hematologic explanation. During preparation for brain imaging, repetitive protrusion and rolling of the tongue provided a recognizable extrapyramidal clue. Medication review then identified newly initiated prochlorperazine, and rapid improvement after intravenous diphenhydramine strengthened the interpretation of dystonia.

This sequence illustrates an important principle for emergency neurology: a stroke mimic should not be inferred solely from an atypical symptom. Instead, the diagnosis became more credible when the movement abnormality, recent dopamine-blocking medication exposure, pharmacological response, and subsequent MRI findings converged. The report’s contribution is consequently a pattern-recognition framework for a high-risk diagnostic setting.

Methods and Experimental Design Insights

This was a single-patient observational case report, not a controlled trial or laboratory experiment. Its method was longitudinal clinical reconstruction: prehospital information, emergency examination, medication history, neurological consultation, imaging, response to treatment, inpatient observation, and follow-up were assembled into one diagnostic narrative. That design cannot measure incidence or comparative risk, but it is well suited to documenting a rare presentation and the clues that changed the working diagnosis.

Protocol Parameters

• Initial presentation: A 32-year-old woman who was 10 weeks pregnant arrived approximately 40 minutes after the onset of slurred speech, left-sided pain, weakness, and paresthesias, according to the case report.
• Medication exposure: Prochlorperazine had been started the day before presentation. She had taken four oral 10 mg doses in total, with the last dose taken one hour before symptom onset, as documented in the reference study.
• Neurological assessment: The initial examination documented intermittent dysarthria and apparent inability to lift the left arm and leg, while facial symmetry, tongue midline position, orientation, and command-following were preserved. Repeated examinations were essential because the signs evolved during the emergency evaluation.
• Extrapyramidal sign: Repetitive tongue protrusion and rolling emerged while the patient was being prepared for head CT. This observation prompted clinicians to revisit the medication history and consider a dystonic reaction rather than relying exclusively on the initial focal-deficit impression.
• Pharmacological challenge: Intravenous diphenhydramine at 50 mg was administered, after which the abnormal motor findings rapidly resolved. The dose and response are reported in the published case; they should be interpreted as case-specific clinical management, not as a universally validated diagnostic test.
• Imaging and observation: Emergency head CT was pursued under the institutional stroke protocol, followed by MRI, which showed no acute stroke. A second dystonic episode occurred during observation and again responded to intravenous diphenhydramine, providing additional temporal support for the diagnosis.

For researchers studying adverse drug reactions, the report demonstrates the value of time-stamped exposure histories and serial phenotyping. A single neurological examination could have captured only weakness and dysarthria, whereas repeated assessments revealed the movement disorder. The response to an anticholinergic antihistamine was informative, but it was interpreted together with imaging and clinical course rather than in isolation. This is a useful design lesson for retrospective chart review and prospective pharmacovigilance: record dose timing, symptom onset, evolving motor signs, rescue treatment, recurrence, and recovery.

Core Findings and Why They Matter

The patient’s symptoms improved rapidly after diphenhydramine, although subjective left-sided weakness did not immediately return to baseline. MRI showed no acute ischemic lesion, and the neurological examination later normalized, including a National Institutes of Health Stroke Scale score of 0, as reported in the reference article. A recurrent dystonic episode during hospital observation also responded to the same treatment. The patient was discharged without long-term neurological sequelae and subsequently had an uneventful term delivery, according to the report.

Several findings carry practical significance. First, unilateral symptoms do not automatically establish a vascular mechanism. Hemidystonia can imitate hemiparesis when abnormal muscle contraction, painful posturing, dysarthria, or poor voluntary movement are interpreted as weakness. Second, oral exposure does not eliminate the possibility of an acute reaction; in this case, the newly introduced medication and recent dose were central clues. Third, the tongue movement was diagnostically disproportionate to its apparent size: a subtle extrapyramidal sign redirected the evaluation.

The case does not argue against urgent stroke imaging. Rather, it supports parallel reasoning. Clinicians should continue time-sensitive stroke assessment while actively searching for medication exposures, seizure-related phenomena, migraine, metabolic disturbances, functional symptoms, and movement disorders. In this report, the negative MRI and sustained clinical recovery helped complete the diagnosis, but neither should be treated as a substitute for the initial emergency evaluation.

Comparison with Existing Internal Articles

The internal article Prochlorperazine: Dopamine D2 Antagonist in Cancer Research frames the compound primarily through pharmacology and experimental applications in melanoma research and virology. That perspective complements the case report by emphasizing the same receptor-level identity, but it addresses laboratory and translational questions rather than acute neurological diagnosis. The stroke-mimic article adds a safety-oriented dimension: dopamine D2 receptor antagonism is not only a mechanistic descriptor but also a reason to monitor for extrapyramidal toxicity.

A second internal resource, Prochlorperazine: Dopamine D2 Antagonist for Melanoma and..., discusses possible uses in cancer research and antiviral workflows. Those topics should not be interpreted as evidence that the reference case demonstrates anticancer or antiviral activity. Instead, the comparison shows how the same compound can appear in distinct evidence streams: the WestJEM publication documents a clinical adverse reaction, whereas the internal articles discuss experimental research contexts. For literature reviews, keeping those domains separate prevents mechanistic plausibility from being mistaken for clinical proof.

Why this cross-domain matters, maturity, and limitations

The cross-domain connection matters because researchers may encounter prochlorperazine in antiemetic therapy, melanoma research, and broader cancer research while interpreting safety or mechanism data. The evidence maturity is uneven. The reference publication is a carefully described single clinical case, useful for hypothesis generation and diagnostic awareness. The internal cancer-focused articles are contextual resources for experimental discussion, not substitutes for peer-reviewed efficacy studies or clinical trials. No conclusion about melanoma cell proliferation, antiviral performance, or oncology benefit can be derived from this stroke-mimic report.

Limitations and Transferability

The strongest limitation is the single-patient design. One case can reveal a previously underrecognized phenotype, but it cannot establish how often prochlorperazine causes hemidystonia, whether pregnancy increases susceptibility, or how the reaction compares with other dopamine-blocking medicines. The patient also had hyperemesis gravidarum and recent surgery, creating clinical context that may not generalize to outpatient antiemetic use or to nonpregnant populations.

Diagnostic attribution was persuasive but not equivalent to experimental proof. Improvement after diphenhydramine, absence of an acute MRI lesion, and recurrence during observation all supported dystonia, yet the report did not include a rechallenge, a comparator drug, or a biomarker specific to drug-induced movement disorders. Residual subjective weakness after the initial motor abnormality resolved also illustrates the complexity of symptom recovery and the risk of treating one response as the complete explanation for every complaint.

Transferability is therefore best understood at the level of process. The report supports repeated neurological examinations, careful medication reconciliation, attention to abnormal oral or cervical movements, and continued imaging when stroke remains plausible. It does not provide a universal decision rule for withholding fibrinolysis or for diagnosing a stroke mimic before vascular disease has been reasonably assessed. In research terms, the case supplies a clinically meaningful signal that could motivate larger pharmacovigilance analyses, but those studies would need systematic exposure data and adjudicated neurological outcomes.

Research Support Resources

Researchers can consult the full reference paper when designing case reviews or safety-focused discussions of dopamine-blocking antiemetics. For laboratory workflows that require this compound, researchers can use Prochlorperazine (SKU A8508) to support similar workflows, while checking the product information, institutional procedures, and appropriate controls before beginning experiments.